INTRODUCTION
Breast cancer (BC) remains a primary driver of cancer-related mortality globally, necessitating the identification of novel molecular targets. While androgen receptor (AR) signaling is a recognized modulator of breast oncology, the therapeutic efficacy of selective androgen receptor modulators (SARMs), par...
M. Yavuz, T. Demircan· Anti-Cancer Agents in Medici...· 0 citations
Personalized mRNA neoantigen vaccines represent an emerging form of precision cancer immunotherapy designed to generate de novo T-cell responses against patient-specific tumor mutations. Their therapeutic activity, however, depends not only on neoantigen selection and vaccine-induced immune priming but also on whether...
T. Demircan, Berna Yıldırım, Halil İbrahim Ünsal et al.· International Journal of Mol...· 0 citations
The inadequacy of traditional preclinical oncology models, specifically two-dimensional (2D) monolayer cultures and murine in vivo systems, in predicting human drug responses has led to the development of patient-derived organoids (PDOs) and microfluidic organ-on-chip (OoC) technologies. These innovations represent sig...
Background: Drug repurposing represents an accelerated and cost-effective approach to discovering novel oncologic therapeutics. Here, we investigated the anticancer potential and underlying mechanisms of marbofloxacin (MBF), a veterinary fluoroquinolone (FQ), against breast cancer (BC) cells. Methods: The cellular impa...
M. Yavuz, F. R. P. Dewi, Ilknur Keskin et al.· Pharmaceuticals· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
